CRISPR Gene Editing Explained

What genes and DNA are

Almost every cell in the body contains a set of instructions called DNA, coiled up in structures called chromosomes. DNA is written in a chemical alphabet of just four letters, and the order of those letters spells out genes, the individual instructions for building the proteins that make our bodies work. If DNA is a giant recipe book, a gene is a single recipe. Sometimes a gene contains a spelling mistake, called a mutation, which can cause the body to make a protein wrongly, or not at all. Many inherited diseases, such as sickle cell disease, are caused by such mistakes. CRISPR is a way of finding and correcting these errors in the code.

How CRISPR works

CRISPR is often described as a pair of molecular scissors with a satnav. It has two main parts. The first is a guide, a short piece of genetic material designed to match a precise spot in the DNA, like a postcode that leads it to the right place. The second is an enzyme, commonly one called Cas9, which acts as the scissors, cutting the DNA at that exact point. Once the DNA is cut, scientists can disable a faulty gene or coax the cell to repair the code in a helpful way. The system is borrowed from bacteria, which use it naturally to defend themselves against viruses. Its power lies in this precision and relative simplicity.

From laboratory to real treatment

For years CRISPR was a laboratory tool, but it has now reached patients. In 2023, UK regulators approved the first CRISPR-based therapy, for sickle cell disease and a related blood disorder called beta thalassaemia. In this treatment, doctors take some of a patient's own blood-forming stem cells, edit them in the laboratory to switch on a helpful form of haemoglobin, and return them to the body. Because the editing is done outside the body and the corrected cells are given back, it avoids editing the patient directly inside. Early results have been striking, freeing some people from a lifetime of pain crises and transfusions. It marks the beginning of a new kind of medicine.

The promise and the limits

CRISPR holds promise for many conditions caused by faults in single genes, and researchers are exploring uses in inherited blindness, some cancers, and other blood and immune disorders. But it is not a magic wand. Editing must be extremely precise, because changing the wrong part of the DNA, an off-target effect, could cause harm. Delivering the tool to the right cells inside the body remains a major challenge. Treatments so far are complex and expensive, raising questions of fair access. Most diseases also involve many genes and lifestyle factors, not a single fault, so CRISPR will help some conditions far more than others. It is a powerful new tool, but one still early in its journey.

The ethical questions

CRISPR raises profound ethical questions that society, not just scientists, must answer. A key distinction is between editing body cells, which affects only the treated person, and editing eggs, sperm or embryos, which would pass changes to future generations. This inheritable, or germline, editing is banned for clinical use in the UK and most countries, because of deep concerns about safety, consent from people not yet born, and the risk of trying to enhance rather than heal. There are also worries about fairness if only wealthy people can afford such treatments. Careful regulation, public debate and international agreement aim to ensure this remarkable technology is used to reduce suffering, safely and fairly, rather than misused.